about
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniaeBiosensor applications in the field of antibiotic research--a review of recent developments.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Identification of a new antimicrobial lysine-rich cyclolipopeptide family from Xenorhabdus nematophila.Activity of Fosfomycin- and Daptomycin-Containing Bone Cement on Selected Bacterial Species Being Associated with Orthopedic Infections.Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections.Antibiotic options for treating community-acquired MRSA.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin.Multidrug-resistant organisms in military wounds from Iraq and Afghanistan.Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections.Pre-clinical experience with daptomycin.The structural diversity of acidic lipopeptide antibiotics.Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machineryInvasive community-associated MRSA infections: epidemiology and antimicrobial management.Treatment of prosthetic osteoarticular infections.Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.Bacterial meningitis: current therapy and possible future treatment options.Drug induced rhabdomyolysis.Current use of daptomycin in cardiac surgery and postoperative intensive care.The Interplay between Daptomycin and the Immune System.Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis.Neuropsychiatric Effects of Antimicrobial Agents.Study on daptomycin use and implementation of an antimicrobial stewardship program.Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans.Systemic antimicrobial therapy in osteomyelitisAn RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.A daptomycin-xylitol-loaded polymethylmethacrylate bone cement: how much xylitol should be used?Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA).Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms.[Daptomycin for the treatment of gram-positive infections after cardiac surgery].Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy.Role of DptE and DptF in the lipidation reaction of daptomycin.Failure of daptomycin to kill Staphylococcus aureus: impact of bacterial membrane fatty acid composition.Daptomycin: a comparison of two intravenous formulations.Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitisMechanism of High-Level Daptomycin Resistance in
P2860
Q24656785-E22BCE28-9D31-4331-873A-EB37C0D4B5CBQ30472227-8F151CC2-E27B-4935-924D-8158C6AF02DCQ33429168-368F49C4-E8C0-4CBC-83C2-8009858BC1A8Q33431190-98C4FB7F-5E9F-4A81-8D49-2AC3A971B4C3Q33581795-11A49F45-BC13-42A8-8F6A-CAC09B564C57Q34308017-775C0AB5-3260-413E-9C03-FBA32E0E2678Q34593646-EF96D97C-0CFF-4CE4-9A2B-CCCCD6727A30Q35617587-E0F7D8DF-E11E-444D-A286-EC4AD109EFACQ35806369-3ABB67BE-B521-47F3-9BE1-93BFB8530000Q36061532-7F4BF6F9-35D2-434D-ABC8-FB43D159922FQ36657841-D55745EB-516D-4329-8BE3-A7AA5925655CQ36888137-5D04A76C-2A3E-4359-A51F-98A8FA82C6C9Q37284356-79EBC6E3-98BE-4BEB-BDBD-D3EE97BC8073Q37373526-A17FBBAA-B1F9-47D3-8A28-87DFE2DADD8CQ37762644-5B42FE3A-FE9B-4284-B9E7-283D5E8698E1Q37800939-B2284423-B956-4BC9-9AE6-A529FCCEFE75Q37853179-2B643EDF-DD9F-4DA3-8F74-018DD4B53EEBQ37875765-F2AE9D4F-020C-49A6-B5D3-2B06B4D6E89BQ37949641-554CD232-5A04-4E28-9E45-B31A67A469B9Q38007737-8EA3A594-F2E7-4C74-B323-5A7CD8DF604BQ38086339-9170822C-EF38-49F4-AAD5-F29283B35562Q38191612-EE9C3665-E9E5-4E1B-974C-C54BE4AB1B2FQ38282693-9A0FED45-042A-411D-B8DD-AD0CC8498936Q39135986-4690CC1E-D278-48E2-B8AF-86DCBD191E83Q40764649-9994F80F-666D-47A4-8B98-A27BE3A2ED68Q40982610-D08A83F2-1372-4A31-88D2-3EA93C29C7DDQ41034745-41BA1695-E288-40AA-AB75-B19755DF231DQ41902616-DE102603-E65F-470D-B0D7-09351A54BEB5Q42115764-8F503DBF-5962-4300-AD86-EF355172033DQ42393393-4328605D-FAF3-4CF4-B845-349A8639BEC8Q42577905-BB1F4535-C237-4311-9348-127F9F397B9AQ44738071-677A90DE-23E5-4AFB-B93A-447BF7BB0BD8Q44899027-88006707-EF8A-4869-893E-5BA338621162Q46286205-0F153D69-3A99-4171-A73A-7FC717920A56Q53686599-CB9860C0-5038-4302-B1C0-85590ABCEBF0Q55518748-34510F20-03DE-49C0-B333-66C910C30E69Q57253129-388B8E59-7304-4232-AAC7-B9687602E9E6Q58795935-28447ADD-F4FF-40E1-BF62-D791784F20EB
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Daptomycin: a review 4 years after first approval.
@en
type
label
Daptomycin: a review 4 years after first approval.
@en
prefLabel
Daptomycin: a review 4 years after first approval.
@en
P2093
P2860
P356
P1433
P1476
Daptomycin: a review 4 years after first approval.
@en
P2093
Christian Joukhadar
Markus Rothenburger
Robert Sauermann
Wolfgang Graninger
P2860
P356
10.1159/000109868
P577
2007-10-16T00:00:00Z